Ribosomal protein S6 kinase alpha-1
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Ribosomal protein S6 kinase alpha-1 as ChEMBL target CHEMBL2553, mapped to UniProt Q15418. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Ribosomal protein S6 kinase alpha-1 matters
Ribosomal protein S6 kinase alpha-1 is reviewed as Ribosomal protein S6 kinase alpha-1 (UniProt Q15418); the current evidence base includes 13 approved drugs, 1824 compounds, and 725 assays, with lead potency reaching pChEMBL 10.1.
Ribosomal protein S6 kinase alpha-1 Sequence length is 735 aa.
Review this target as Ribosomal protein S6 kinase alpha-1, mapped to UniProt Q15418. Sequence length is 735 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 13 approved drugs, 1824 compounds, and 725 assays for this target. The dominant activity type is KD. CHEMBL388978 is the current potency anchor at pChEMBL 10.1.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 10.1).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Ribosomal protein S6 kinase alpha-1 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q15418, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL3683258
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL5273774
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL5956719
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL5776408
|
9.3 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |